EC Number   |
Activating Compound |
Reference  |
|---|
   3.4.24.87 | Urea |
required |
650714 |
| 3.4.24.87 | Ristocetin |
activates |
650715 |
| 3.4.24.87 | more |
low salt concentrations activate the proteolytic activity |
650717 |
| 3.4.24.87 | Urea |
activation, substrate is degraded at 1 M |
650717, 650725 |
| 3.4.24.87 | Urea |
activates at 1 M |
652481 |
| 3.4.24.87 | more |
CCl4 at concentration of 6.5 mM does not directly enhance the activity of ADAMTS-13 |
670063 |
| 3.4.24.87 | Rituximab |
a monoclonal anti-CD 20 antibody, Rituximab leads to a prompt reduction in IgG antibody levels, followed by an increase in ADAMTS 13 activity increases. However, in patients receiving Rituximab electively, normalisation of ADAMTS 13 enzyme activity may be delayed for up to 3 months |
711559 |
| 3.4.24.87 | more |
substrate modified by alpha2-3,6,8,9-neuraminidase from Arthrobacter ureafaciens removing alpha2-3- and alpha2-6-linked sialic acid results in reduced ADAMTS13 activity |
711575 |
| 3.4.24.87 | more |
cleavage of von Willebrand factor A2 requires the force-induced A2 unfolding |
711576 |
| 3.4.24.87 | more |
mild denaturation of fluid shear stress increase the hydrolysis of von Willebrand factor |
711809 |
